Our results indicate that reduced VEGFR-3 levels could have a detrimental effect on the immunological anti-tumor response in an early stage of primary tumor growth, through impaired lymphangiogenesis and IL-6 elevation. This evidence concerns the gene FLT4 and neoplasm.